BUND FINANCE

BUND FINANCE › Stocks › ILMN

Illumina, Inc. (ILMN)

NASDAQ · Stock price, chart and technical analysis

US$210.01+7.40 (+3.65%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$202.61
OpenUS$202.98
Day rangeUS$200.79 – US$211.88
52-week rangeUS$112.65 – US$309.35
Market capUS$31.75B
Volume1.63M
50-day averageUS$248.45
200-day averageUS$180.09
Beta1.45

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$4.5BUS$4.6BUS$4.5BUS$4.4BUS$4.3B
Net incomeUS$762.0M−US$4.4B−US$1.2B−US$1.2BUS$850.0M
EPS (diluted)5.05-28.05-7.35-7.695.45
Gross margin69.7%64.8%60.9%65.4%66.1%
Operating margin-2.7%-91.2%-23.7%-19.1%18.6%
Net margin16.8%-96.1%-25.8%-28.0%19.6%
Free cash flowUS$337.0MUS$106.0MUS$283.0MUS$709.0MUS$931.0M
Total debtUS$2.5BUS$3.6BUS$2.3BUS$2.6BUS$2.6B
CashUS$1.2BUS$2.0BUS$1.0BUS$1.1BUS$1.4B

Compound annual growth: revenue -1.0% · net income 2.8% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E36.1x48.7x27.1x
EV / EBITDA23.6x31.5x16.5x
Operating margin22.4%—3.6%
Net margin19.7%—-0.0%
Debt / equity1.17—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Illumina, Inc.

SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryUS
CEOJacob Thaysen
Employees8,600
IPO date2000-07-28

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and …

www.illumina.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice